BGB-A317-30813-101: This study will test whether taking a new anti-cancer drug (called BGB-30813) alone, or in addition to targeted therapy (called tislelizumab) can help treat people with cancer that has spread throughout the body or is locally advancedA Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors

Summary

This is study has two stages. Stage 1 (dose escalation) has got two experimental arms. In Stage 1 Arm A, participants will receive escalating doses of BGB-30813 alone. In Stage 1 Arm B, participants will receive escalating doses of BGB-30813, and they will also receive tislelizumab. This first stage is trying to find the dose that is best tolerated. BGB-30813 will be given orally and tislelizumab will be given through a vein. The second stage (Dose Expansion) will further test the dose of BGB-30813 selected in the first stage, either alone or with tislelizumab. This stage is testing whether the treatments can improve the signs and symptoms of their cancer.